Figure 4 | Scientific Reports

Figure 4

From: The differential effects of tumor burdens on predicting the net benefits of ssCART-19 cell treatment on r/r B-ALL patients

Figure 4

Cytokine release syndrome and neurotoxic effects after infusion of ssCART-19 cells. (A) Correlation between the CRS level and tumor burden (P = 0.0080; t test). (B) Correlation between the occurrence of sCRS and the tumor burden (P = 0.0053; Fisher's exact test). (C) Correlation between the occurrence of sCRS and the tumor burden subgroup (P = 0.0224; one-way ANOVA); no CRS means CRS level 0, normal CRS means CRS levels 1 and 2, and sCRS means CRS level 3 or higher. (D) No correlation was observed between the occurrence of neurotoxic effects and the tumor burden (P > 0.9999; Fisher's exact test).

Back to article page